Recombinant Factor VIIA, its Clinical Properties, and the Tissue Factor Pathway of Coagulation

Bosinski, Timothy J

doi:10.2174/138955706778560201

Cited by 2 publications

(2 citation statements)

References 52 publications

(65 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with rFVIIa, the use of RMPs is advantageous in several ways. While the procoagulant activity of rFVIIa is mediated by tissue factor activation, 26 RMPs do not have tissue factor and are least likely to induce thrombosis. 10 Second, RMPs enhance both primary and secondary hemostasis (both intrinsic and extrinsic pathways), 10 while rFVIIa only enhance secondary hemostasis.…”

Section: Discussionmentioning

confidence: 99%

Red Blood Cell Microparticles Limit Hematoma Growth in Intracerebral Hemorrhage

Rehni

Cho

Quero

et al. 2022

Stroke

View full text Add to dashboard Cite

Background: Spontaneous intracerebral hemorrhage (sICH) is the deadliest stroke subtype with no effective therapies. Limiting hematoma expansion is a promising therapeutic approach. Red blood cell-derived microparticles (RMPs) are novel hemostatic agents. Therefore, we studied the potential of RMPs in limiting hematoma growth and improving outcomes post-sICH. Methods: sICH was induced in rats by intrastriatal injection of collagenase. RMPs were prepared from human RBCs by high-pressure extrusion. Behavioral and hematoma/lesion volume assessment were done post-sICH. The optimal dose, dosing regimen, and therapeutic time window of RMP therapy required to limit hematoma growth post-sICH were determined. We also evaluated the effect of RMPs on long-term behavioral and histopathologic outcomes post-sICH. Results: RMP treatment limited hematoma growth following sICH. Hematoma volume (mm 3 ) for vehicle- and RMP- (2.66×10 10 particles/kg) treated group was 143±8 and 86±4, respectively. The optimal RMP dosing regimen that limits hematoma expansion was identified. RMPs limit hematoma volume when administered up to 4.5-hour post-sICH. Hematoma volume in the 4.5-hour post-sICH RMP treatment group was lower by 24% when compared with the control group. RMP treatment also improved long-term histopathologic and behavioral outcomes post-sICH. Conclusions: Our results demonstrate that RMP therapy limits hematoma growth and improves outcomes post-sICH in a rodent model. Therefore, RMPs have the potential to limit hematoma growth in sICH patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Red Blood Cell Microparticles Limit Hematoma Growth in Intracerebral Hemorrhage

Rehni

Cho

Quero

et al. 2022

Stroke

View full text Add to dashboard Cite

show abstract

“…The drug is reported to be used prophylactically in surgery or patients without a coagulopathy, such as in cerebral bleeding or from tissue factor (T.F.) exposure at sites not associated with tissue injury, such as unstable coronary plaques [15,16] .…”

Section: Introductionmentioning

confidence: 99%

Recombinant Factor VII for the Conservative Management Trials of Intractable Postpartum Haemorrhage: Is it a Drug Effect, Operator Experience or Inherent Result of the Aetiology

Azizi¹,

Eldin²

2022

Evidence Based Women's Health Journal

View full text Add to dashboard Cite

Aim: This monocentric retrospective study aimed at the evaluation of outcome of the parturients with intractable postpartum haemorrhage (P.P.H.) after the administration of recombinant activated factor VII (rFVIIa) to preserve the uterus. Materials and Methods: this is a retrospective study conducted in a tertiary hospital . 41 patients were selected based on the inclusion criteria of both suffering from postpartum hemorrhage and received recombinant activated factor VII (rFVIIa). Patients were divided into group A who were managed by senior staff and group B who had started their management by junior staff and senior staff was called later for the case. Data was retrieved from patients' records during 2019. All patients had a preliminary evaluation and classic management measures for postpartum hemorrhage either in the emergency department or during planned cesarean section. If are still bleeding, patients were infused with rFVIIa. If the uterine bleeding didn't stop, conservative management was cancelled, and abdominal hysterectomy was done. In all cases, postpartum mortality was determined. Results:The study included 41 parturient with P.P.H. with a mean age of 30.8±5.4 years. Eighteen patients had a cesarean section (C.S.), of whom 8 had successfully conserved the uterus, and 10 patients had a lifesaving hysterectomy using rFVIIa. On the other hand, 23 patients had been complicated with intractable postpartum haemorrhage. Twenty patients successfully had conservative management after using rFVIIa, and 3 patients had failed conservative management after using rFVIIa, and hysterectomy was lifesaving. Regarding 7-day postpartum mortality, one patient died with an intractable haemorrhage with delayed hysterectomy. Conclusion:The operator seniority and experience is more important than the use of rFVIIa to achieve conservative management of cases suffering from or at great risk of postpartum hemorrhage and to reduce patients mortality.

show abstract

Recombinant Factor VIIA, its Clinical Properties, and the Tissue Factor Pathway of Coagulation

Cited by 2 publications

References 52 publications

Red Blood Cell Microparticles Limit Hematoma Growth in Intracerebral Hemorrhage

Red Blood Cell Microparticles Limit Hematoma Growth in Intracerebral Hemorrhage

Recombinant Factor VII for the Conservative Management Trials of Intractable Postpartum Haemorrhage: Is it a Drug Effect, Operator Experience or Inherent Result of the Aetiology

Contact Info

Product

Resources

About